FOLH1 and glycogen storage disease VI: In this retrospective study, the incidence of PSMA PET/CT bone-only disease in a CRPC population was 20%, showing that PSMA PET/CT reliably identifies bone metastases in CRPC patients, opening the door for bone-targeted therapies and potentially improving treatment sequences.